MaxCyte joins the Alliance for mRNA Medicines (AMM) as a founding member

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced that it has joined the Alliance for mRNA Medicines (AMM), as a founding member.

NGS made effortless: introducing MIRO CANVAS from INTEGRA Biosciences

INTEGRA Biosciences is excited to announce the launch of MIRO CANVAS, a compact digital microfluidics platform for fully automated next-generation sequencing (NGS) sample preparation.

September 22, 2023

Intarcia’s diabetes drug-device combo voted down again by FDA panel

A Food and Drug Administration advisory committee voted unanimously on Thursday afternoon to reject an appeal for Intarcia Therapeutics’ Type 2 diabetes drug-device combination treatment,

September 25, 2023

Upside for competitor manufacturers due to Novo-Catalent deal unlikely to be immediate, Samsung Bio exec says

Even if competitor manufacturers attract the attention of Catalent’s customers on the back of it being acquired by Novo Holdings, it will take time for

March 9, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.